Rhythm Pharmaceuticals (RYTM) PT Raised to $129 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RYTM Hot Sheet
Price: $86.63 +0.22%
Rating Summary:
19 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
19 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $129.00 (from $122.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Rhythm Pharmaceuticals (RYTM) PT Lowered to $146 at Morgan Stanley
- NICE expands Imcivree reimbursement to adults with Bardet-Biedl
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
